HER2 Support Group Forums - View Single Post - Music to your ears....Dr. Sledge's prediction on her2+ breast cancer

Lani · 06-28-2014, 02:10 AM

J Community Support Oncol. 2014 Mar;12(3):78-81.
Is the era of HER2 over? Pertuzumab in the neoadjuvant treatment of early HER2-positive breast cancer.
Samuel TA1, Stone E.
Author information

Abstract
At the ASCO Breast Cancer Symposium in San Francisco last year, the keynote speaker, Dr George Sledge, chief of oncology at Stanford University School of Medicine and a preeminent breast cancer researcher, gave his 5 predictions for the state of breast cancer care in 10 years. One of his more startling predictions was that in 10 years, he believed that the era of HER2/neu would be over. He predicted that 3-year disease-free survival for patients with HER2/neu-positive disease would more than 92%, approximating outcomes in other good prognosis malignancies such as testicular cancer. In view of that expectation, he believed that the main research questions regarding HER2- positive disease would eventually involve decreasing toxicity and costs rather than the improving efficacy of HER2-targeted therapy. Essentially, HER2/neu-positive disease would cease to be a public health issue. In view of this remarkable but likely prescient statement, we note the recent publication of 2 trials (NeoSphere and TRPHAENA) that examined the efficacy and safety of the use of pertuzumab in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of early-stage HER2-positive breast cancer.
PMID: 24971410

06-28-2014, 02:10 AM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Music to your ears....Dr. Sledge's prediction on her2+ breast cancer J Community Support Oncol. 2014 Mar;12(3):78-81. Is the era of HER2 over? Pertuzumab in the neoadjuvant treatment of early HER2-positive breast cancer. Samuel TA1, Stone E. Author information Abstract At the ASCO Breast Cancer Symposium in San Francisco last year, the keynote speaker, Dr George Sledge, chief of oncology at Stanford University School of Medicine and a preeminent breast cancer researcher, gave his 5 predictions for the state of breast cancer care in 10 years. One of his more startling predictions was that in 10 years, he believed that the era of HER2/neu would be over. He predicted that 3-year disease-free survival for patients with HER2/neu-positive disease would more than 92%, approximating outcomes in other good prognosis malignancies such as testicular cancer. In view of that expectation, he believed that the main research questions regarding HER2- positive disease would eventually involve decreasing toxicity and costs rather than the improving efficacy of HER2-targeted therapy. Essentially, HER2/neu-positive disease would cease to be a public health issue. In view of this remarkable but likely prescient statement, we note the recent publication of 2 trials (NeoSphere and TRPHAENA) that examined the efficacy and safety of the use of pertuzumab in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of early-stage HER2-positive breast cancer. PMID: 24971410